Estrogen Receptor Modulators

• 

  Subject Areas on Research

  • Breast cancer: hormones and other risk factors. 
  • Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. 
  • Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. 
  • Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. 
  • Development of peptide antagonists that target estrogen receptor-cofactor interactions. 
  • Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. 
  • Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. 
  • The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. 
  • The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. 
  • Toxicology of environmental estrogens. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute